March 16, 2021
Cambridge, Ontario – Novocol Pharmaceutical, a long-established sterile injectable fill-finish organization that provides clinical and commercial-scale manufacturing services for global customers, announced today that it will receive a contribution of up to $32.7 million from the Government of Canada to strengthen domestic biomanufacturing capacity. The contribution is made though the Strategic Innovation Fund (SIF) and will support a project to expand Novocol’s GMP facilities in Cambridge, Ontario, with fill-finish capacity to enhance Canada’s responsiveness to future pandemics.
“Canada’s biomanufacturing sector is rich in knowledge and expertise. By investing in domestic biomanufacturing facilities and equipment, such as Novocol, we are investing in made-in-Canada solutions to fight COVID-19 while retaining and developing the expertise necessary to help us secure vaccine and therapy supply chains here at home. Our government is committed to rebuilding Canada’s biomanufacturing sector, focusing on both short-term strategic solutions and a long-term vision.”
- The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry (Government of Canada).
“Novocol is grateful for the support from the Government of Canada through the Strategic Innovation Fund. This investment will increase domestic biomanufacturing capacity for fill-finish of sterile injectables including vaccines, therapeutics, and a wide range of pharmaceuticals in a state-of-the-art GMP facility expansion. By creating such capacity and capabilities, Novocol will contribute to strengthening Canada’s preparedness for future pandemics, as well as create skilled jobs and economic development in the country’s biopharmaceutical ecosystem. As a contract development and manufacturing organization (CDMO), our investment will provide valuable services to support Canadian and foreign biopharmaceutical innovators, starting from clinical trial materials through to commercial scale manufacturing”
- Olivier Schiller, CEO of Novocol Pharma’s French-based parent company, Septodont.
“We are honoured to receive SIF support for this pivotal expansion of Novocol Pharma’s injectable fill-finish operations in Cambridge, Ontario. The project will build upon Novocol’s forty years of sterile manufacturing experience through expanded fill-finish capabilities for vaccines and innovative biopharmaceuticals in vials and syringes. The COVID-19 pandemic has highlighted the need for a vibrant domestic biomanufacturing ecosystem, with available capacity to respond to pandemics. The Novocol team is proud to contribute to Canada’s emergency preparedness and biomanufacturing strategies. We also look forward to growing with our CDMO clients as a trusted value chain partner. We are thankful to our parent company, Septodont, for choosing to invest in Canada”
- Atif Zia, President of Novocol Pharma.
Find the official Innovation, Science and Economic Development Canada press release here.
About Novocol Pharma
Novocol Pharma is a sterile injectable fill-finish organization based in Cambridge, Ontario. The company provides contract clinical and commercial-scale manufacturing services for global customers. For more information, please visit www.novocolpharma.com.
For media inquiries, please contact:
+ 33 6 45 70 04 43
For all other inquiries, please visit: